Characteristics of IBD population surveyed in relation to risk groups as per British Society of Gastroenterology COVID-19 IBD guidelines
| Risk groups | ||||
| High | Moderate | Low | Total | |
| Age (years) median (IQR) | 41 (28) | 34.5 (17.3) | 32 (23) | |
| Gender | ||||
| Female | 28 (26%) | 67 (62%) | 13 (12%) | 108 (47.3%) |
| Male | 49 (41%) | 61 (51%) | 10 (8%) | 120 (52.6%) |
| Ethnicity | ||||
| Caucasian | 48 (33%) | 84 (58%) | 12 (8%) | 144 (63.2%) |
| South Asian | 26 (38%) | 34 (50%) | 8 (12%) | 68 (29.8%) |
| Black | 3 (19%) | 10 (63%) | 3 (19%) | 16 (7%) |
| IBD phenotype | ||||
| CD | 52 (34%) | 88 (57%) | 14 (9%) | 154 (67.5%) |
| UC | 25 (34%) | 40 (54%) | 9 (12%) | 74 (32.5%) |
| Current medical therapy | ||||
| Mesalazine | 15 (28%) | 17 (32%) | 21 (40%) | 53 (23.2%) |
| Thiopurine | 31 (33%) | 63 (67%) | 0 (0%) | 94 (41.2%) |
| Methotrexate | 2 (100%) | 0 (0%) | 0 (0%) | 2 (0.9%) |
| Tofacitinib | 1 (33%) | 2 (67%) | 0 (0%) | 3 (1.3%) |
| Infliximab | 26 (37%) | 45 (63%) | 0 (0%) | 71 (31.1%) |
| Adalimumab | 12 (31%) | 27 (69%) | 0 (0%) | 39 (17.1%) |
| Vedolizumab | 4 (27%) | 11 (73%) | 0 (0%) | 15 (6.6%) |
| Ustekinumab | 13 (48%) | 14 (52%) | 0 (0%) | 27 (11.8%) |
| Combination therapy(biologic +immunomodulator) | 18 (35%) | 34 (65%) | 0 (0%) | 52 (22.8%) |
There were no significant differences in ethnicity, age, gender or IBD phenotype between risk groups. Overall immunosuppression use was significantly greater in the moderate-risk group (p<0.001) compared with the high-risk group.
CD, Crohn's disease; IBD, inflammatory bowel disease; UC, ulcerative colitis.